Risks and benefits of biologic therapy for inflammatory bowel diseases
- 1 May 2007
- Vol. 56 (5), 725-732
- https://doi.org/10.1136/gut.2006.103564
Abstract
Many patients who receive treatment with biologic agents have received other therapies or continue to use concomitant therapies to which the biologics are added (box 1). It is …Keywords
This publication has 38 references indexed in Scilit:
- Infliximab for Rheumatoid Arthritis in a Patient with TuberculosisNew England Journal of Medicine, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisThe American Journal of Gastroenterology, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Bias in analytic researchJournal of Chronic Diseases, 1979